Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy

Table 2

Disease characteristics and treatment response.

Patient	Stage*	Recurrent	Gross disease	Posttreatment response within the irradiated volume	Months until PD (in or out of irradiated volume)
1	T4N2bM0	No	Yes	PR	6.4 (in)
2	T0N2bM0	Yes	Yes	CR	14.7 (in), 16.3 (out)
3	T0N2bM0R0	Yes	No	N/A	(Died with NED)
4	T4N0M0	Yes	Yes	SD	(Died without PD)
5	T0N1M0	Yes	Yes	CR	(Alive with NED)
6	T4N0M0	Yes	Yes	SD	(Alive with NED)
7	T2N2bM0	No	Yes	PD (during treatment)	1.7 (in and out)
8	T0N2bM1	Yes	Yes	CR	2.1 (out), 5.0 (in)
9	T2N2bM0	Yes	Yes	CR	4.4 (out)
10	T4N0M0	Yes	Yes	SD	52.2 (in)
11	T0N3M1	Yes	Yes	PR	1.6 (out)
12	T4N0M0	No	Yes	PR	4.4 (out), 4.7 (in)

Disease status at the start of therapy and investigator assessed response 4–12 weeks after therapy are presented.
∗All patients were staged clinically, except patient 3, who was staged pathologically.
PR: partial response, CR: complete response, SD: stable disease, PD: progressive disease, NED: no evidence of disease, IV: irradiated volume, and N/A: not applicable (because patient received adjuvant therapy [no measureable disease for response assessment]).